GFL
VRTX icon

Granite FO LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Granite FO LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97K Hold
8
– – ﹤0.01% 112
2026
Q1 		$3.57K Hold
8
– – ﹤0.01% 115
2025
Q4 		$3.63K Hold
8
– – ﹤0.01% 123
2025
Q3 		$3.13K Hold
8
– – ﹤0.01% 143
2025
Q2 		$3.56K Hold
8
– – ﹤0.01% 131
2025
Q1 		$3.88K Hold
8
– – ﹤0.01% 127
2024
Q4 		$3.22K Hold
8
– – ﹤0.01% 132
2024
Q3 		$3.72K Buy
+8
New +$3.84K ﹤0.01% 128
2024
Q2 		– Sell
-8
Closed -$3.92K – 183
2024
Q1 		$3.92K Buy
+8
New +$3.38K ﹤0.01% 138

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Granite FO LLC's VRTX Position: Q2 2026 in Review

Granite FO LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 8 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #112.

Granite FO LLC first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Granite FO LLC held 8 shares of Vertex Pharmaceuticals worth $3.97K as of Q2 2026.
  • Granite FO LLC left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Granite FO LLC's portfolio in Q2 2026, its #112 holding.
  • Granite FO LLC first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Granite FO LLC's 13F filing for Q2 2026, filed 15 Jul 2026.